Hepatology (Baltimore, Md.)

• 

  Publication Venue For

  • Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art..  74:2233-2240. 2021
  • Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart..  71:1867-1869. 2020
  • Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list..  66:1144-1150. 2017
  • Ignore reality but not the consequences of its ignorance: Broaden guidelines in surgery of hepatocellular carcinoma..  65:1772-1773. 2017
  • Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).  62:1386A-1386A. 2015
  • NADPH oxidase-induced TLR4 recruitment to hepatic lipid rafts mediates NASH progression.  60:1289A-1289A. 2014
  • Intrahepatic landscape of regulatory T-cell subsets in chronically HCV-infected patients with cirrhosis and HCC..  60:1461-1462. 2014
  • Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver..  59:2065-2067. 2014
  • Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations.  59:661-670. 2014
  • A Phase 2B Double-Blind Placebo Controlled Study of Two Doses of EPA-E in Patients With Nonalcoholic Steatohepatitis.  58:1385A-1385A. 2013
  • Reply.  50:994. 2009
  • Reply.  50:655-656. 2009
  • Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis..  45:1366-1374. 2007
  • Bile ductules and stromal cells express hedgehog ligands and/or hedgehog target genes in primary biliary cirrhosis..  45:1091-1096. 2007
  • Sertraline as a first-line treatment for cholestatic pruritus..  45:666-674. 2007
  • Liver-specific loss of beta-catenin results in delayed hepatocyte proliferation after partial hepatectomy..  45:361-368. 2007
  • Growth factors during HCV therapy may be "cost-effective", but are they "effective"?.  44:1400-1403. 2006
  • Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice..  44:1267-1277. 2006
  • Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management..  44:1039-1046. 2006
  • Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo..  43:1074-1083. 2006
  • Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice..  43:817-825. 2006
  • HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C..  43:241-249. 2006
  • Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease..  42:880-885. 2005
  • HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis..  42:496-497. 2005
  • A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism..  42:156-164. 2005
  • Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis..  41:943. 2005
  • Chronological development of elevated aminotransferases in a nonalcoholic population..  41:64-71. 2005
  • Tinkering and tailoring with HCV therapy: can we get away with less?.  40:1249-1251. 2004
  • Norepinephrine regulates hepatic innate immune system in leptin-deficient mice with nonalcoholic steatohepatitis..  40:434-441. 2004
  • Vascular interference: a blockade to tumor epithelial growth..  39:1491-1494. 2004
  • Gut flora-based therapy in liver disease? The liver cares about the gut..  39:1197-1200. 2004
  • Risks of a range of alcohol intake on hepatitis C-related fibrosis..  39:826-834. 2004
  • Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease..  39:403-411. 2004
  • Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes..  38:653-663. 2003
  • Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver..  38:703-714. 2003
  • Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury..  38:664-673. 2003
  • CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease..  38:428-435. 2003
  • Cytokine network during NASH and possible treatment selection..  38:530. 2003
  • Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?.  38:21-24. 2003
  • A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy..  37:1368-1374. 2003
  • Elevated hepatocyte levels of the Forkhead box A2 (HNF-3beta) transcription factor cause postnatal steatosis and mitochondrial damage..  37:1414-1424. 2003
  • Noninvasive prediction of fibrosis in patients with chronic hepatitis C..  37:1220-1221. 2003
  • Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients..  37:1222. 2003
  • Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease..  37:343-350. 2003
  • Future therapy of hepatitis C..  36:S245-S252. 2002
  • Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus..  36:1206-1213. 2002
  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication..  36:211-218. 2002
  • Nonalcoholic fatty liver disease: an agenda for clinical research..  35:746-752. 2002
  • A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis..  35:535-543. 2002
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin..  35:688-693. 2002
  • Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease?.  35:731-732. 2002
  • Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology..  34:694-706. 2001
  • Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression..  34:168-179. 2001
  • The role of Smad3 in mediating mouse hepatic stellate cell activation..  34:89-100. 2001
  • Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda..  33:406-412. 2001
  • Mechanisms of ischemic injury are different in the steatotic and normal rat liver..  32:1280-1288. 2000
  • Effect of bilirubin UDP glucuronosyltransferase 1 gene TATA box genotypes on serum bilirubin concentrations in chronic liver injuries..  32:563-568. 2000
  • Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate..  32:418-426. 2000
  • Clinical relevance of hepatitis B viral mutations..  31:1037-1044. 2000
  • Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage..  31:633-640. 2000
  • Kupffer cells mediate leukocyte and platelet synergism causing sinusoidal endothelial cell apoptosis of the cold ischemic rat liver.  32:208A-208A. 2000
  • Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study..  31:225-229. 2000
  • Ceramide analogue B13 induces apoptosis and completely inhibits growth of liver metastases from colon cancer in vivo a new strategy for the treatment of metastatic liver disease..  30:161A-161A. 1999
  • Using outcomes data to identify best medical practice: The role of policy models.  29. 1999
  • Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: a clinical and electrophysiologic study..  29:1698-1703. 1999
  • Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up..  29:1893-1899. 1999
  • Using outcomes data to identify best medical practice: The role of policy models.  29:36S-39S. 1999
  • Using outcomes data to identify best medical practice: the role of policy models..  29:36S-39S. 1999
  • P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver..  29:1494-1502. 1999
  • Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure..  29:1317-1323. 1999
  • Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver..  29:1131-1138. 1999
  • Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice [correction of rat] liver..  29:677-687. 1999
  • Platelets cause sinusoidal endothelial cell apoptosis of the cold ischemic rat liver: A new target in liver transplantation..  28:405A-405A. 1998
  • Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation..  27:1652-1660. 1998
  • Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America..  27:1661-1669. 1998
  • Interleukin 1beta-stimulated production of nitric oxide in rat hepatocytes is mediated through endogenous synthesis of interferon gamma..  27:711-719. 1998
  • Magnetic resonance microscopy and histopathology: comparative approach of bromobenzene-induced hepatotoxicity in the rat..  27:526-532. 1998
  • Dysregulation of proteoglycan production by intrahepatic biliary epithelial cells bearing defective (delta-f508) cystic fibrosis transmembrane conductance regulator..  27:7-14. 1998
  • Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent..  26:1513-1520. 1997
  • Kupffer cell depletion abolishes induction of interleukin-10 and permits sustained overexpression of tumor necrosis factor alpha messenger RNA in the regenerating rat liver..  25:889-895. 1997
  • E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma..  24:1460-1467. 1996
  • Hepatic regeneration is associated with preservation of microsomal glucuronidation..  24:1250-1255. 1996
  • Keratinocyte growth factor--just another mitogen or the "Holy Grail" that regulates liver regeneration?.  22:1886-1888. 1995
  • Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding..  22:1474-1481. 1995
  • CLONING, FUNCTIONAL-CHARACTERIZATION AND TISSUE EXPRESSION OF THE RAT-LIVER P-2U RECEPTOR.  22:790-790. 1995
  • EXPRESSION OF THE CELL-ADHESION MOLECULE CD44 IN PRIMARY TUMORS OF THE LIVER.  22:1606-1606. 1995
  • THE EFFECTS OF POSTOPERATIVE COMPLICATIONS ON QUALITY-OF-LIFE PARAMETERS AFTER ORTHOTOPIC LIVER-TRANSPLANTATION.  22:140-140. 1995
  • The physiology of jaundice: molecular and functional characterization of the Crigler-Najjar syndromes..  22:1338-1340. 1995
  • Tumor necrosis factor-alpha modulates CCAAT/enhancer binding proteins-DNA binding activities and promotes hepatocyte-specific gene expression during liver regeneration..  22:252-261. 1995
  • Vitamin E therapy of acute CCl₄ -induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding.  22:1474-1481. 1995
  • Renin and angiotensinogen mRNA expression in the kidneys of rats subjected to long-term bile duct ligation..  19:1431-1436. 1994
  • Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells..  19:1445-1452. 1994
  • Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency..  19:339-345. 1994
  • Regenerative changes in C/EBP alpha and C/EBP beta expression modulate binding to the C/EBP site in the c-fos promoter..  19:447-456. 1994
  • Transforming growth factor-beta 1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat..  19:412-417. 1994
  • Long-term ethanol consumption alters the hepatic response to the regenerative effects of tumor necrosis factor-alpha..  17:1066-1073. 1993
  • Chronic ethanol consumption disturbs G-protein expression and inhibits cyclic AMP-dependent signaling in regenerating rat liver..  16:1212-1219. 1992
  • Alcohol-related trafficking accidents..  15:964-966. 1992
  • Transport of free fatty acid and triglyceride in anhepatic rats..  14:911-919. 1991
  • Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119)..  14:581-589. 1991
  • Bile salts stimulate glycoprotein release by guinea pig gallbladder in vitro..  13:957-961. 1991
  • Ethanol interferes with regeneration-associated changes in biotransforming enzymes: a potential mechanism underlying ethanol's carcinogenicity?.  13:722-727. 1991
  • Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance.  14:581-589. 1991
  • Supplemental putrescine reverses ethanol-associated inhibition of liver regeneration..  12:633-637. 1990
  • 2 DIMENSIONAL GEL-ELECTROPHORETIC PATTERNS OF BILIARY PROTEIN SECRETION AFTER LIVER-TRANSPLANTATION.  10:659-659. 1989
  • THE RELATIVE EFFECT OF LOVASTATIN (L) ON TOTAL (TC), LOW-DENSITY LIPOPROTEIN (LDL-C) CHOLESTEROL AND ON THE BILIARY CHOLESTEROL SATURATION INDEX (SI) IN SUBJECTS WITH GALLSTONES.  10:735-735. 1989
  • A simplified single stage total hepatectomy in the rat with maintenance of gastrointestinal absorptive function..  9:69-74. 1989
  • DEATHS FROM GALLSTONES - INCIDENCE AND ASSOCIATED CLINICAL FACTORS.  8:1373-1373. 1988
  • EFFECT OF CHEMICAL HEPATIC SYMPATHECTOMY ON BASAL AND GLUCAGON STIMULATED BILIARY-SECRETION.  8:1288-1288. 1988
  • The effect of chronic ethanol feeding on ornithine decarboxylase activity and liver regeneration..  8:237-242. 1988
  • Alpha 1-adrenergic effects and liver regeneration..  7:1189-1194. 1987
  • Effect of parenteral amino acid supplementation in alcoholic hepatitis..  5:57-63. 1985
  • Time course and mechanism of alterations in proton relaxation during liver regeneration in the rat..  5:538-543. 1985
  • Gallbladder glycoprotein secretion in mice with hemolytic anemia and pigment gallstones..  3:198-200. 1983
  • DISTINCTIVE EFFECTS OF DIET ON THE HEPATIC MIXED-FUNCTION OXIDASE SYSTEM IN RATS AFTER PORTACAVAL ANASTOMOSIS.  3:806-806. 1983
  • Without victory there is no survival: transarterial lipiodol chemoembolization and hepatocellular carcinoma..  28:270-271. 1998
  • Beta-hydroxybutyrate and niacin protect the murine liver from acute inflammatory injury via activation of the Gpr109 receptor.  Volume 60:501-509.
  • AHRR METHYLATION MEDIATES THE EFFECTS OF MATERNAL SMOKING ON LIVER FAT CONTENT AND METABOLIC HEALTH IN CHILDREN 2022
  • AN AUTOMATIC LOW FLOW ASCITES PUMP IMPROVES ASCITES CONTROL AND QUALITY OF LIFE IN PATIENTS WITH CIRRHOSIS AND RECURRENT ASCITES 2022
  • IMPROVING THE CARE OF VETERANS WITH ELEVATED FIBROSIS-4 INDEX SCORES 2022
  • LOWER ANTI-MULLERIAN HORMONE, A MARKER OF REDUCED OVARIAN RESERVE, IS INDEPENDENTLY ASSOCIATED WITH PRESENCE AND SEVERITY OF NASH IN PRE- -MENOPAUSAL WOMEN 2022
  • METABOLITE EXPRESSION IN PATIENTS WITH HIV INFECTION WITH AND WITHOUT HCV CO-INFECTION: FINDING COMMON GROUND WITH NON-ALCOHOLIC FATTY LIVER DISEASE 2022
  • PRE-TEENS EXPOSED PRENATALLY TO MATERNAL OBESITY EXHIBIT PERSISTENT DNA METHYLATION CHANGES THAT ASSOCIATE WITH METABOLIC ABNORMALITIES, INCLUDING HIGH LIVER FAT 2022
  • BIOMARKERS, IMAGING AND SAFETY IN RESMETIROM 52 WEEK NON-CIRRHOTIC NASH PHASE 3 CLINICAL TRIAL, COMPLETED OPEN-LABEL ARM OF MAESTRO-NAFLD-1 2021
  • COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS 2021
  • EVEN MODEST ELEVATIONS IN LIVER FAT ASSOCIATE WITH METABOLIC ABNORMALITIES IN CHILDREN AND MAY INDICATE FUTURE RISK FOR NAFLD AND ASSOCIATED COMPLICATIONS 2021
  • HIPPO-YAP PATHWAY IS A MASTER REGULATOR OF HEPATIC STELLATE CELL SENESCENCE AND FERROPTOSIS SUSCEPTIBILITY 2021
  • ICD CODES INCREASE ACCURACY OF COMPUTABLE PHENOTYPES IN EMR-BASED IDENTIFICATION OF NAFLD 2021
  • IMPLICATIONS OF GERIATRIC SYNDROMES ON POST-LIVER TRANSPLANT DELIRIUM IN PATIENTS WITH CIRRHOSIS 2021
  • LIVER VOLUME REDUCTION IN RESMETIROM TREATED NON-CIRRHOTIC AND CIRRHOTIC NASH PATIENTS 2021
  • SINGLE CELL RNA SEQUENCING DATA FROM MICE IDENTIFIES INHIBITED HEDGEHOG SIGNALING IN HEPATOCYTES AS A CRITICAL EARLY EVENT IN HUMAN NAFLD 2021
  • TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS 2021
  • VALIDATION OF A METABOLOMIC SIGNATURE AS A PREDICTOR OF END-STAGE LIVER DISEASE EVENTS IN PEOPLE WITH HIV/HCV COINFECTION 2021
  • ALGORITHM FOR PREDICTING ADVANCED NASH FIBROSIS ON SCREENING BIOPSY IN RESMETIROM PHASE 3 MAESTRO-NASH CLINICAL TRIAL 2020
  • BLACK, OLDER, UNMARRIED, AND MEDICAID PATIENTS WERE LESS LIKELY TO COMPLETE HEPATOLOGY VIDEO VISITS DURING COVID-19 2020
  • CHANGE IN LIVER FAT CONTENT AT 4 WEEKS ACCURATELY PREDICTS CHANGE IN LIVER FAT CONTENT AT 12 WEEKS IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS TREATED WITH AN FXR AGONIST: ANALYSIS FROM A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH MET409 2020
  • DYNAMIC EPIGENETIC REPROGRAMMING ENABLES FUNCTIONAL DIVERSIFICATION OF HEPATOCYTES DURING LIVER REGENERATION 2020
  • FINAL ANALYSIS OF A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ALDAFERMIN (NGM282) IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS 2020
  • HEPATOCELLULAR CARCINOMA TUMOR BURDEN SCORE TO STRATIFY PROGNOSIS AFTER LIVER TRANSPLANTATION. 2020
  • HISTORY OF BREASTFEEDING IS ASSOCIATED WITH A DECREASED RISK OF HEPATIC FIBROSIS AMONG YOUNG WOMEN WITH NAFLD 2020
  • HYPERHOMOCYSTEINEMIA IS A MARKER AND MEDIATOR OF NASH: DISCOVERY OF A NOVEL VITAMIN THERAPY (B12 AND FOLATE) FOR NASH 2020
  • LIPID MANAGEMENT IN A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALDAFERMIN (NGM282) 2020
  • LONGITUDINAL CHANGES OF PRO-C3 AND ELF ARE ASSOCIATED WITH HISTOLOGIC AND CLINICAL DISEASE PROGRESSION IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) 2020
  • NONALCOHOLIC FATTY LIVER AND ITS RISK FACTORS ASSOCIATE WITH DIFFERENTIAL DNA METHYLATION IN THE PERIPHERAL BLOOD OF PRE-TEENAGE CHILDREN 2020
  • OPPORTUNITIES FOR EARLY DIAGNOSIS OF UNRECOGNIZED CIRRHOSIS IN THE DEPARTMENT OF VETERANS AFFAIRS 2020
  • PREDICTIVE FACTORS FOR PROLONGED INVASIVE MECHANICAL VENTILATION IN CHILDREN POST LIVER TRANSPLANT 2020
  • QUALITY OF HEPATITIS B VIRUS-RELATED CARE IN PATIENTS WITH HBV MONOINFECTION AND HBV/HIV COINFECTION UNDER GI OR ID CARE: A NATIONAL VHA COHORT STUDY 2020
  • RISK OF CARDIOVASCULAR DISEASE IN NON-OBESE INDIVIDUALS WITH NONALCOHOLIC FATTY LIVER DISEASE 2020
  • RISK OF HCC IN PATIENTS WITH HBV INFECTION WITH AND WITHOUT HIV CO-INFECTION: A US ADMINISTRATIVE CLAIMS ANALYSIS 2020
  • SERUM AFP AS A DIAGNOSTIC MARKER OF HEPATOCELLULAR CARCINOMA IN LIRADS M LESIONS 2020
  • TESTOSTERONE IS A KEY RISK FACTOR FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS IN YOUNG PRE-MENOPAUSAL WOMEN WITH FATTY LIVER 2020
  • THE RNA BINDING PROTEIN ZFP36L1 MAINTAINS HEPATOCYTE MATURITY IN HEALTHY ADULT LIVER 2020
  • TREATMENT WITH RESMETIROM IN PHASE 3 MAESTRO-NAFLD-1 NASH STUDY OPEN LABEL ARM: EFFECTS ON BIOMARKERS AND IMAGING 2020
  • UNIQUE METABOLIC PROFILES CHARACTERIZE ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND CARDIOVASCULAR DISEASE 2020
  • UTILITY OF A NOVEL DRUG INDUCED LIVER INJURY CAUSALITY ASSESSMENT TOOL (DILI-CAT) FOR ADJUDICATION OF DILI IN DRUG DEVELOPMENT. 2020
  • VARIABILITY IN CONSENT FOR HCV NAT plus ORGANS ON THE LIVER TRANSPLANT WAITING LIST. 2020
  • YAP SIGNALING DICTATES CELL-STATE-DEPENDENT FERROPTOSIS SUSCEPTIBILITY IN HEPATIC STELLATE CELLS 2020
  • A LARGE PROPORTION OF NAFLD PATIENTS WITH ADVANCED FIBROSIS REMAIN CLINICALLY UNIDENTIFIED: AN ANALYSIS OF PCORNET DATA 2019
  • ACCEPTABLE LIVER TRANSPLANTATION OUTCOMES AMONG OLDER RECIPIENTS WITH HCC DESPITE HIGHER-RISK FEATURES ON EXPLANT IN A LARGE MULTICENTER US COHORT (REALT) 2019
  • ASSOCIATIONS BETWEEN SEROLOGIC MARKERS OF EXTRACELLULAR MATRIX (ECM) REMODELING WITH FIBROSIS STAGE AND PROGNOSIS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC) 2019
  • COURSE OF CIRRHOSIS REGRESSION: LESSONS FROM PATIENTS WITH HCV CIRRHOSIS FOLLOWING SUCCESSFUL SOFOSBUVIR-BASED TREATMENT 2019
  • DISCOVERY OF ERAP2 GENE EXPRESSION AS A RISK FACTOR FOR DRUG-INDUCED LIVER INJURY DUE TO AMOXICILLIN-CLAVULANIC ACID. 2019
  • DONATION AFTER CARDIAC DEATH LIVER TRANSPLANT HAS NO IMPACT ON RENAL INJURY OR RENAL FAILURE IN RECIPIENTS OF ADVANCED AGE 2019
  • EFFECTS OF RESMETIROM (MGL-3196) ON HEPATIC FAT, LIPIDS, LIVER ENZYMES AND MARKERS OF LIVER FIBROSIS IN AN OPEN-LABEL 36-WEEK EXTENSION STUDY IN NASH PATIENTS 2019
  • EFFICACY AND ADHERENCE TO ORAL HEPATITIS C (HCV) TREATMENT THROUGH A DIGITAL MEDICINE PROGRAM (DMP) AMONG A POPULATION AT HIGH RISK FOR NONADHERENCE 2019
  • EXPRESSION OF BRANCHED CHAIN AMINO ACID TRANSAMINASE 1 (BCAT1) IS INCREASED IN NAFLD FIBROSIS AND CIRRHOSIS AND HEPATOCELLULAR CARCINOMA 2019
  • MET409, A SUSTAINED FXR AGONIST, DECREASED HEPATIC FAT AND IMPROVED LIVER FUNCTION WITHOUT RAISING LDL-C AFTER 28 DAYS IN NASH PATIENTS 2019
  • METASTATIC DISEASE DOES NOT HAVE A NEGATIVE IMPACT ON PATIENT SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION- A HEPATOBLASTOMA TRANSPLANT CONSORTIUM STUDY 2019
  • OUTCOMES OF LIVER TRANSPLANTATION AMONG OLDER RECIPIENTS WITH NASH IN A LARGE MULTICENTER US COHORT (REALT) 2019
  • PRIMARY BILE ACID AND BRANCHED CHAIN AMINO ACID METABOLITES ASSOCIATE WITH DIASTOLIC HEART FAILURE IN NON-ALCOHOLIC FATTY LIVER DISEASE 2019
  • RESCUE TRANSPLANT OUTCOMES IN HEPATOBLASTOMA - A TRANSPLANT CONSORTIUM STUDY 2019
  • RNA-SEQ FROM PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS IDENTIFIES A FIBROSIS-INDEPENDENT GENE EXPRESSION SIGNATURE THAT PREDICTS CLINICAL EVENTS 2019
  • SAFETY AND EFFICACY OF MARALIXIBAT IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: AN OPEN-LABEL PROOF-OF-CONCEPT STUDY 2019
  • STEATOSIS AND FIBROSIS MEASURED AS CONTINUOUS VARIABLES ON PAIRED, SERIAL LIVER BIOPSIES IN THE RESMETIROM (MGL-3196) 36-WEEK PHASE 2 NASH STUDY 2019
  • THE ASSOCIATION BETWEEN OBESITY OR DIABETES AND LIVER DISEASE PROGRESSION AFTER ANTIVIRAL TREATMENT FOR HEPATITIS C 2019
  • VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN MANAGEMENT OF HIV/HCV COINFECTION 2019
  • Yap1 AS A THERAPEUTIC TARGET IN FIBROLAMELLAR CARCINOMA 2019
  • ADVANCED FIBROSIS IS ASSOCIATED WITH INCIDENT CARDIOVASCULAR DISEASE IN PATIENTS WITH BIOPSY-PROVEN NAFLD 2019
  • NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study 2018
  • NGM313, a Novel Once-Monthly Activator of beta-Klotho/FGFR1c, Significantly Reduces Hepatic Steatosis and Key Biomarkers of Nonalcoholic Steatohepatitis: Results of a Randomized, Active-Controlled Clamp Study in Obese Insulin Resistant Patients with NAFLD 2018
  • "If I Get Cured, My Whole Quality of Life Will Change": an in-Depth Qualitative Analysis of Patients' Anticipated Benefits If Cured from Hepatitis C Viral (HCV) Infection 2018
  • Improvements in Symptoms Shortly Following Viral Cure for Chronic Hepatitis C: A Large Multi-Site Clinical Cohort Study 2018
  • In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with Mgl-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy 2018
  • Lipidomic Signature As a Predictor of Liver Disease Events in HIV/HCV Co-Infectedpatients 2018
  • NGM282 Rapidly Improves NAFLD Activity Score (NAS) and Fibrosis in 12 Weeks in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH): Results of a Phase 2 Multi-Center Dose Finding Study 2018
  • Obesity and Nonalcoholic Fatty Liver Disease in Childhood Associate with Altered DNA Methylation in Early Life 2018
  • Patient-Reported Symptom Experiences Are Heterogeneous during Direct Acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Real-World Cohort Study 2018
  • Prevalence and Predictors of Medication Non-Adherence in a Multi-Center Cohort Treated with Hepatitis C Direct-Acting Antivirals: Results from the Patient-Reported Outcomes Project (PROP-UP) 2018
  • Prognostic Utility of Ammonia Testing on Admission in Cirrhotic Patients with and without Acute on Chronic Liver Failure (ACLF) 2018
  • Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials 2018
  • Senescence-Associated Reprogramming Promotes Hepatocarcinogenesis in Nonalcoholic Steatohepatitis 2018
  • The Alcohol Use Disorders Identification Test Screening in Patients with Hepatitis C 2018
  • The Impact of Advanced Age on Waiting List and Post-Transplantation Outcomes for NAFLD Patients 2018
  • The Impact of Graft Type on Outcome in Pediatric Liver Transplantation: An Updated Report from 2011-2017 from the Studies of Pediatric Liver Transplantation (SPLIT) Group 2018
  • Yap1 As a Therapeutic Target in Fibrolamellar Carcinoma 2018
  • A National Audit of Paediatric to Adult Transition Liver Services in the UK 2018
  • Alcoholic Liver Disease Has Rapidly Emerged As the Leading Indication for Liver Transplant Evaluation 2018
  • Factors Associated with Nonalcoholic Fatty Liver Disease in HIV 2018
  • Long-Term Aspirin Use and Risk for Fibrosis Progression, in a Prospective Population with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease (NAFLD) 2018
  • Predictors of Incident Cardiovascular Disease in Adults with Biopsy-Proven NAFLD 2018
  • Predictors of Low Bone Mineral Density in Post-Menopausal Women with NAFLD 2018
  • Women with Alcoholic Liver Disease Are Less Likely to be Listed for Liver Transplantation. 2018
  • 100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals) 2017
  • A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC) 2017
  • Altered liver methylome and transcriptome provide evidence for epigenetic contribution to NAFLD pathogenesis 2017
  • Diabetes, duration of diabetes, use of anti-diabetic medications, and risk of hepatocellular carcinoma 2017
  • Diet/exercise programs are used by only one in five severely obese patients with biopsy-defined Nonalcoholic Fatty Liver Disease (NAFLD) advanced fibrosis in the Veterans Health Administration (VHA) 2017
  • Fructose-Related Hepatic ATP Depletion Induces Hyperuricemia in Healthy Volunteers and Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. 2017
  • Gender and menopause significantly modify effects of metabolism-related SNPs on fibrosis stage in adult patients with nonalcoholic fatty liver disease (NAFLD) 2017
  • Hepatocellular injury and senescence in NASH are linked to Hedgehog and Hippo pathway activity and accumulation of hepatic progenitor cells 2017
  • Higher rates and significant disparities in the risk and phenotypes of amoxicillin:clavulanate-related liver injury were observed in the Veterans Health Administration (VHA) 2017
  • Minocycline and anti-epileptics are the leading causes of DILI in Children 2017
  • Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis 2017
  • Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance 2017
  • Radiologic progression in primary sclerosing cholangitis (PSC) by two-dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial 2017
  • Testing for Hepatitis C Virus RNA is Recommended in Patients with Suspected Drug Induced Liver Injury (DILI) 2017
  • Visceral and subcutaneous adipose tissue measurements associate with increased metabolic risk for NAFLD in pre-pubertal obese children 2017
  • GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial 2016
  • A Novel Computerized Drug Induced Liver Injury Causality Assessment Tool (DILI-CAT) 2016
  • An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA 2016
  • BCAT1 is Associated with Clinical Decompensation in NAFLD: A Pilot Study 2016
  • Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program 2016
  • Cholangiocyte chemokine secretion and macrophage accumulation is mediated by osteopontin in murine liver models 2016
  • Cost-effectiveness of a risk-stratified hepatocellular carcinoma surveillance strategy in patients with cirrhosis 2016
  • Drug Induced Liver Injury Associated with Sclerosing Cholangitis Like Changes on Magnetic Resonance Cholangiography Imaging 2016
  • Hedgehog-responsive Myofibroblasts activate Yes-associated Protein (Yap) 1 and Promote TGFb-Signaling to Induce Epithelial-Mesenchymal Transitions in Hepatocytes during Murine Liver Regeneration 2016
  • Hepatic estrogen transcriptional activity and estrogen receptor a gene expression are negatively correlated with fibrosis stage in patients with nonalcoholic fatty liver disease (NAFLD) 2016
  • Hepatic expression of lysyl oxidase-like-2 ( LOXL2) in primary sclerosing cholangitis (PSC) 2016
  • Hepatic stellate cell Yes-associated protein 1 (Yap1) is necessary for liver regeneration 2016
  • Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with Concomitant Acid Suppressing Medication 2016
  • High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials. 2016
  • Idiosyncratic drug induced liver injury in African Americans: Causes, Clinical Features and Outcomes 2016
  • Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer 2016
  • Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection 2016
  • Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens 2016
  • MMP9 is a potential mediator of TWEAK-Fn14 signaling in a rodent model of acute alcoholic steatohepatitis 2016
  • Phenotypic Differences in Primary Sclerosing Cholangitis by Age Group 2016
  • Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts 2016
  • TRPV4 prevents tissue injury in diseased fatty liver by blocking CYP2E1-mediated redox-toxicity via Kupffer cell-induced nitric oxide production 2016
  • The Impact of HLA Serotyping and HLA Matching for PSC, PSC/AIH, AIH, PBC/AIH, and PBC Patients on Post-Liver Transplant Graft Failure: an Analysis of the UNOS Database 2016
  • Vitamin D is Not Associated with Histologic Severity in NAFLD: Results of a Paired Clinical and Hepatic Gene Expression Profile Analysis 2016
  • Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study 2015
  • Ancestral starvation-activated caspase-2 promotes obesity, the metabolic syndrome and Nonalcoholic fatty liver disease 2015
  • Association between elevated serum IgG4 (sIgG4) concentrations and the phenotype of patients with primary sclerosing cholangitis (PSC) 2015
  • Characterization of insulin resistance in patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) 2015
  • Characterization of obesity-related modifications in hepatic stellate cells 2015
  • Clinical and histologic correlates of the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) 2015
  • Cross-sectional and longitudinal agreement of magnetic resonance imaging proton density fat fraction with pathologist grading of hepatic steatosis in adults with nonalcoholic steatohepatitis in a multi-center trial 2015
  • DNA Methylation Profiles of Fibrosis-Associated Gene in Blood Reflects Liver Fibrosis Severity in Human Nonalcoholic Fatty Liver Disease 2015
  • Death and Liver Transplantations Occurring Within Two Years of Drug-Induced Liver Injury 2015
  • Detecting Drug-Induced Liver Injury in Patients with Decompensated Chronic Hepatitis C: A Review of the SOLAR-1 and SOLAR-2 Studies 2015
  • Expression of matrix metalloproteinase 9 (MMP9) and the apoptosis signal-regulating kinase 1 (ASK1) pathway activation marker, phospho-P38 (p-P38), in primary sclerosing cholangitis (PSC) 2015
  • Genome-wide investigation identifies common SNPs on Chr9p22.2 as risk factors for liver injury due to sulfa-methoxazole/trimethoprim 2015
  • HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds 2015
  • Hepatitis B Testing Prior to Administration of Rituximab, Ofatumumab and Obinutuzumab in the National Veterans Affairs Health Healthcare System, 2002-2014 2015
  • IL-8 and MCP1 are Independently Associated with Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease 2015
  • Impact of NGM282 on the Incidence and Severity of Pruritus in Primary Biliary Cirrhosis Patients and Correlations with Liver Chemistries and Serum Bile Acids 2015
  • Increasing severity of NAFLD is associated with gut dysbiosis and modification of the metabolic function of the gut microbiota 2015
  • NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial 2015
  • Nocturnal Hypoxia is associated with Hedgehog Signaling and Severity of Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD) 2015
  • Osteopontin promotes cholangiocyte chemokine secretion and macrophage accumulation in mice 2015
  • Plasma Metabolomic Profiles Predict Advanced Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver Disease 2015
  • Predictive value of APRI and FIB4 scores for liver fibrosis assessment in comparison to Transient Elastography in chronic hepatitis C patients 2015
  • Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH) 2015
  • Severe and prolonged jaundice associated with body building supplements (BBS): review of 44 cases from the Drug-Induced Liver Injury Network (DILIN) 2015
  • Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension 2015
  • TRPV4 deficiency enhances TLR4 recruitment to lipid rafts exhibiting exacerbated stellate cell activation and fibrosis in experimental nonalcoholic steatohepatitis 2015
  • TRPV4 regulates inflammation and Kupffer cell activation in nonalcoholic steatohepatitis by attenuation of CYP2E1-mediated oxidative stress 2015
  • The Epidemiology of Suspected Drug Induced Liver Injury in the US: The Delaware Liver Injury Study 2015
  • Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy 2015
  • Validation of serum fibrosis marker panels in patients with primary sclerosing cholangitis (PSC) in a randomized trial of simtuzumab 2015
  • Cholestatic Drug reactions are more likely to cause persistent liver injury and impaired Quality of Life during prolonged follow-up: Results from the DILIN Prospective study 2014
  • Hedgehog-signaling and angiogenesis in cirrhotic and non-cirrhotic portal hypertension 2014
  • Hepatic Stellate Cells Express the Hepatocyte-enriched Transcription Factor, Hepatocyte Nuclear Factor 4 alpha 2014
  • High morbidity and mortality in end-stage liver disease and heart failure 2014
  • Improved but persistent poor functional performance at 1 year after liver transplantation: Predictors of performance and opportunities for intervention 2014
  • M1 Polarization bias and subsequent NASH progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1 induced oxidative stress 2014
  • Micro RNA 21 inhibition of SMAD 7 enhances fibrogenesis via leptin mediated NADPH oxidase in experimental nonalcoholic steatohepatitis 2014
  • Osteopontin mediates fibrogenic effects of leptin and enhances NASH progression 2014
  • Outcomes for Patients with Decompensated Cirrhosis Transferred from Outlying Hospitals to a Tertiary Care Liver Transplant Center 2014
  • Patient-Reported Outcomes (PROs) in HIV-HCV Co-infected Patients Treated with Sofosbuvir (SOF)-containing Regimens 2014
  • Repair-related Activation of Hedgehog Signaling in Stromal Cells Promotes Intrahepatic Hypothyroidism 2014
  • Risk of severe fibrosis is associated with age at menopause in nonalcoholic fatty liver disease (NAFLD) 2014
  • Safety and Efficacy of Ledipasvir/Sofosbuvir Single-Tablet-Regimen in African Americans with Genotype 1 Chronic Hepatitis C Virus: A Retrospective Analysis of Phase 3 Studies 2014
  • Safety and Efficacy of Sofosbuvir-Containing Regimens for Hepatitis C: Real-World Experience in a Diverse, Longitudinal Observational Cohort 2014
  • Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials 2014
  • Specialty Care is Associated with Early Diagnosis of Hepatitis C-related Hepatocellular Carcinoma in US Veterans 2014
  • The Influence of Race on Patient Preferences and Access to Orthotopic Liver Transplantation and Organ Donation 2014
  • Whole Exome Sequencing of Extreme Phenotypes of NAFLD Identifies Potential Genetic Risk Factors for Advanced Hepatic Fibrosis 2014
  • Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation: Preliminary Results of a Prospective, Multicenter Study 2013
  • Absence of FN14 Ameliorates Acute Ethanol-Induced Steatohepatitis 2013
  • All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1) 2013
  • CYP2E1-dependent and Leptin-induced CD57-positive cytotoxic T cells are crucial for progression of nonalcoholic steatohepatitis 2013
  • Cholangiocyte proliferation and Osteopontin secretion is induced by Schistosoma mansoni egg antigens and correlates with fibrosis and portal hypertension in human and murine schistosomiasis 2013
  • Hedgehog Pathway Targeted by Vitamin E Therapy in NASH 2013
  • Hedgehog Signaling by Hepatic Epithelial Progenitor Cells Forming Neotubules Drives Parenchymal Fibrogenesis in Gestational Alloimmune Liver Disease 2013
  • Hedgehog-Induced Serine Biogenesis is Required for Activation of Hepatic Stellate Cells 2013
  • Osteopontin enhances liver progenitor cell responses in progressive Nonalcoholic Steatohepatitis 2013
  • Purinergic Receptor X7 is a Key Modulator of Metabolic Oxidative Stress - Mediated Autophagy and Inflammation in Experimental Nonalcoholic Steatohepatitis 2013
  • Safety Profile of Peginterferon Lambda for Treatment of Chronic Hepatitis B (CHB) or Chronic Hepatitis C (CHC): Cross-Study Analysis of Patients Treated in Three Phase 2 Studies 2013
  • The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational Study 2013
  • The Rising Burden of Herbal and Dietary Supplement Induced Hepatotoxicity in the U. S. A 2013
  • The Role of Pleiotrophin Signaling in the Hepatic Stem Cell Niche 2013
  • Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET) 2013
  • Complications of Deceased Donor Liver Transplant: A Meta-Analysis of Reported Incidences 2013
  • Using In-person and Video Observations to Assess Safety Vulnerabilities in Living Donor Liver Transplantation 2013
  • A Systematic Review of Racial and Ethnic Diversity of Hepatitis C Virus Clinical Trials 2012
  • Activation Of Hedgehog Pathway In Schistosomiasis Mansoni And Its Relationship With Liver Fibrosis 2012
  • Automated Extraction of Quality Indicators for Hospitalized patients with cirrhosis and ascites 2012
  • Clinical Decision Tool for Predicting Treatment Week Eight Response and Sustained Virologic Response in Patients Treated with Boceprevir (BOC) Plus Peginterferon Alfa and Ribavirin (PR) 2012
  • Expression QTL analysis of a gene expression signature which predicts advanced non-alcoholic fatty liver disease 2012
  • GI-5005 Therapeutic Vaccine Enhances Virologic Clearance By Peg-IFN/Ribavirin In Naive HCV Genotype 1 Patients With IL28B Genotype T/T 2012
  • Hyponatremia in Hospitalized Patients with Cirrhosis: Interim Data from an Observational, Prospective, MultiCenter, Global Hyponatremia Registry Indicates Hyponatremia is Still Present at Discharge 2012
  • Impact of Gender and Menopause on Histologic Severity of Inflammation and Injury in patients with Nonalcoholic Fatty Liver Disease 2012
  • Improved SVR in a unique cohort of non-cirrhotic thrombocytopenic patients with hepatitis C virus (HCV) treated in the global multicenter ENABLE 1 and 2 trials 2012
  • Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C 2012
  • Osteopontin regulates viral permissivity and replication in Huh7.5 cells infected with Hepatitis C Virus 2012
  • Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naive Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b 2012
  • Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa) 2012
  • Potential role for intrahepatic CD34+cells in immunity to hepatitis C virus 2012
  • Profiles of Leukocytes Infiltrating Livers of Subjects with Drug-Induced Liver Injury (DILI) 2012
  • Reliability of the Drug Induced Liver Injury Network (DILIN) Expert Opinion Process in the Diagnosis of DILI 2012
  • Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients 2012
  • Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naive HCV Patients: Interim Results of a Prospective, Randomized Trial 2012
  • Subject race and liver biochemical profile are strongly associated with clinical outcomes and chronic liver injury: Results from the DILIN Prospective study 2012
  • Targeted proteomics signature identifies corticosteroid binding globulin peptides as highly predictive of treatment response in IL28B unfavorable genotype patients 2012
  • What Factors Explain Excess Risk of Death among Black Liver Transplant Recipients? 2012
  • Whole-exome sequencing identifies rare genetic variants that may contribute to isoniazid (INH)-induced liver injury 2012
  • ABROGATION OF CANONICAL HEDGEHOG ACTIVITY DECREASES HEPATIC FIBROSIS 2011
  • AUTOCRINE ACTIVATION OF THE HEDGEHOG PATHWAY DURING LIVER SINUSOIDAL ENDOTHELIAL CELL CAPILLARIZATION 2011
  • DOSE DEPENDENT ASSOCIATION OF FRUCTOSE CONSUMPTION WITH HYPERURICEMIA AND INSULIN RESISTANCE IN CHILDREN WITH NAFLD 2011
  • DRUG-INDUCED LIVER INJURY (DILI) MODULATED BY CONCOMITANT USE OF TARGETED DRUG CLASSES: AN ANALYSIS OF 303 DRUGS ASSOCIATED WITH HEPATOTOXICITY 2011
  • GREEN TEA EXTRACT CONTAINING HERBAL & DIETARY SUPPLEMENTS ARE FREQUENTLY MISLABELED IN THE USA: THE US DRUG-INDUCED LIVER INJURY NETWORK (DILIN) EXPERIENCE 2011
  • HEDGEHOG PATHWAY ACTIVATION OCCURS IN PULMONARY MICROVASCULATURE DURING EXPERIMENTAL HEPATOPULMONARY SYNDROME (HPS) 2011
  • HEDGEHOG PATHWAY INHIBITION BY GDC-0449 CAUSES REGRESSION OF HEPATOCELLULAR CARCINOMAS AND IMPROVES LIVER FIBROSIS IN MDR2-DEFICIENT MICE 2011
  • HEDGEHOG PATHWAY INHIBITION INDUCES HCC TUMOR NECROSIS BY REPRESSING EXPRESSION OF ANGIOPOIETIN-2 AND ITS COGNATE RECEPTOR, TIE-2 2011
  • HIV/HCV-COINFECTED NATURAL VIRAL SUPPRESSORS HAVE BETTER VIROLOGIC RESPONSES TO PEG-IFN AND RIBAVIRIN THAN ARV-TREATED HIV/HCV PATIENTS 2011
  • IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS 2011
  • IL28B POLYMORPHISM IS NOT ASSOCIATED WITH HCV PROTEASE DIVERSITY IN HIV/HCV-COINFECTED PATIENTS TREATED WITH AN INTERFERON-BASED REGIMEN 2011
  • IMPACT OF CONCOMITANT MEDICATIONS ON DRUG-INDUCED LIVER INJURY: DATA MINING ANALYSIS USING THE WHO VIGIBASE (TM) DATABASE 2011
  • INFLUENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE-1 (G1) SUBTYPE, BASELINE VIRAL LOAD AND IL28B GENOTYPE ON PEGINTERFERON (PEG)/RIBAVIRIN (RBV) TREATMENT RESPONSE: RESULTS OF THE IDEAL STUDY 2011
  • INTERFERON alpha-2B BY CONTINUOUS SUBCUTANEOUS INFUSION IN COMBINATION WITH RIBAVIRIN FOR TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS: 12 WEEK INTERIM ANALYSIS 2011
  • ITPA GENE POLYMORPHISMS SIGNIFICANTLY AFFECT HEMOGLOBIN DECLINE AND TREATMENT OUTCOMES IN HIV/HCV CO-INFECTED PATIENTS 2011
  • METABOLOMIC ANALYSIS DEMONSTRATES HEPATITIS C VIRUS GENOTYPES G2/3 SELECTIVELY PERTURB DISTAL STEPS IN CHOLESTEROL BIOSYNTHESIS 2011
  • PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC) 2011
  • PORTAL VENOUS FLOW ABNORMALITIES ARE PRESENT AND ARE ACCENTUATED AFTER ISCHEMIA REPERFUSION INJURY OF A STEATOTIC LIVER 2011
  • PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS 2011
  • THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM 2011
  • TRANSITION OF QUIESCENT STELLATE CELLS INTO MYOFIBROBLASTS REQUIRES HEDGEHOG-MEDIATED INDUCTION OF GLYCOLYSIS 2011
  • VITAMIN D AND TREATMENT RESPONSE IN AFRICAN AMERICAN PATIENTS WITH HCV GENOTYPE 1 2011
  • PEDF IS NECESSARY FOR NORMAL INSULIN SIGNALING 2011
  • ADDITION OF PROBIOTICS TO PROPRANOLOL IMPROVES RESPONSE FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS AND LARGE ESOPHAGEAL VARICES 2010
  • CHANGES IN ALT AND VITAMIN E LEVELS AND HISTOLOGICAL RESPONSE IN PATIENTS WITH NASH TREATED WITH VITAMIN E IN THE PIVENS TRIAL 2010
  • CO-CULTURE OF LIVER EPITHELIAL CELLS STABLY TRANSFECTED WITH HEPATITIS B VIRUS X PROTEIN PROMOTES MYOFIBROBLASTIC ACTIVATION AND ACCUMULATION VIA A HEDGEHOG-MEDIATED PROCESS IN RAT HEPATIC STELLATE CELLS 2010
  • COMMON GENETIC VARIANTS DO NOT ASSOCIATE WITH IFN-INDUCED NEUTROPENIA IN A GENOME-WIDE ASSOCIATION STUDY OF CHRONIC HEPATITIS C PATIENTS IN THE IDEAL STUDY 2010
  • CONSERVED GENE EXPRESSION PATTERNS IN MYOFIBROBLASTIC MURINE AND HUMAN HEPATIC STELLATE CELLS AND NAFLD PATIENTS WITH LIVER FIBROSIS COMPATIBLE WITH EPITHELIAL-TO-MESENCHYMAL LIKE TRANSITION 2010
  • DEFECTIVE LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IN MICE LACKING FIBROBLAST GROWTH FACTOR INDUCIBLE 14 2010
  • DEPRESSION AND ANXIETY SCORES ARE INDEPENDENTLY ASSOCIATED WITH HISTOLOGIC SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE 2010
  • FRUCTOKINASE POLYMORPHISMS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE ARE ASSOCIATED WITH DECREASED URIC ACID AND THE PRESENCE OF HEPATIC FIBROSIS 2010
  • GENOME WIDE-ASSOCIATION STUDY IDENTIFIES IL28B POLYMORPHISM TO BE ASSOCIATED WITH BASELINE ALT AND HEPATIC NECRO-INFLAMMATORY ACTIVITY IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY 2010
  • GENOME-WIDE ASSOCIATION STUDY IDENTIFIES AN ASSOCIATION BETWEEN ITPA GENE VARIANTS AND IFN-INDUCED THROMBOCYTOPENIA IN CHRONIC HEPATITIS C PATIENTS FROM THE IDEAL STUDY 2010
  • HEDGEHOG PATHWAY DRIVES THE ACQUISITION OF MESENCHYMAL MARKERS IN DUCTULAR CELLS OF PATIENTS WITH BILIARY ATRESIA 2010
  • HEDGEHOG PATHWAY INHIBITOR IS A SAFE AND EFFECTIVE TREATMENT FOR HEPATOCELLULAR CARCINOMA IN MDR2-/- MICE WITH CHRONIC LIVER DISEASE 2010
  • HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE 2010
  • IL28B GENETIC POLYMORPHISM HAS GENOME WIDE SIGNIFICANT ASSOCIATIONS WITH SERUM LOW DENSITY LIPOPROTEIN LEVELS AND HEPATIC STEATOSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC) 2010
  • IL28B GENOTYPE IS NOT ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY 2010
  • IL28B PLASMA LEVELS IN PATIENTS WITH DISTINCT IL28B SNP POLYMORPHISMS AND ASSOCIATION WITH TREATMENT OUTCOME 2010
  • IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS 2010
  • IMO-2125, A TLR9 AGONIST, INDUCES IMMUNE RESPONSES WHICH CORRELATE WITH REDUCTIONS IN VIRAL LOAD IN NULL RESPONDER HCV PATIENTS 2010
  • IMPAIRED FASTING GLUCOSE IS ASSOCIATED WITH LOWER RATES OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC): RETROSPECTIVE ANALYSIS OF THE IDEAL STUDY 2010
  • INCREASED PRODUCTION OF SONIC HEDGEHOG BY BALLOONED HEPATOCYTES: IMPLICATIONS FOR FIBROSIS PROGRESSION IN NASH 2010
  • ITPA GENETIC VARIANTS ARE PROTECTIVE AGAINST ANEMIA DURING ANTIVIRAL THERAPY FOR G2/3 HCV, BUT DO NOT DECREASE THE NEED FOR RBV DOSE REDUCTION OR INCREASE SVR 2010
  • MACROPHAGE-DERIVED HEDGEHOG LIGANDS PROMOTES FIBROGENIC RESPONSES IN SCHISTOSOMIASIS MANSONI 2010
  • MYOFIBROBLAST-DERIVED TGF beta PROMOTES BILIARY TREE GROWTH DURING CHOLESTATIC LIVER INJURY BY SUPPRESSING ANGIOPOIETIN 1/TIE2/TRYPTOPHAN HYDROXYLASE 2 AXIS AND SEROTONIN SECRETION IN NEIGHBORING CHOLANGIOCYTES 2010
  • NASH INCREASES THE RISK OF PORTAL VEIN THROMBOSIS IN PATIENTS ON THE LIVER TRANSPLANT WAITING LIST 2010
  • NR4A NUCLEAR ORPHAN RECEPTORS ARE NOVEL REGULATORS OF HEPATIC FIBROSIS 2010
  • OBSTRUCTIVE SLEEP APNEA WORSENS HEPATIC INFLAMMATION AND FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE 2010
  • OSTEOPONTIN PROMOTES NONALCOHOLIC FATTY LIVER DISEASE PROGRESSION 2010
  • PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12 2010
  • ROLE OF GLP-1R AGONISTS IN DECREASING HEPATIC STEATOSIS AND APOPTOSIS IN OB/OB MICE UNDERGOING ISCHEMIA REPERFUSION INJURY 2010
  • SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON alpha 2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS 2010
  • SIGNALS FROM THE FIBROTIC LIVER IN PATIENTS WITH NAFLD MAY PROMOTE DIABETES AND OBESITY 2010
  • TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY 2010
  • THE IL28B CC GENOTYPE STRONGLY PREDICTS EARLY VIRAL KINETICS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON-RIBAVIRIN 2010
  • VARIANTS IN THE ITPA GENE PROTECT AGAINST EARLY RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN HIV/HCV CO-INFECTED PATIENTS 2010
  • GENDER AND HORMONAL STATUS ARE ASSOCIATED WITH SEVERITY OF HISTOLOGIC FEATURES AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE 2009
  • HEDGEHOG SIGNALING, STELLATE CELL/ENDOTHELIAL CELL CROSS-TALK AND PROGRESSION OF VIRAL HEPATITIS 2009
  • HEDGEHOG-RELATED ACCUMULATION OF NKT CELLS PROMOTES FIBROGENESIS IN PROGRESSIVE NON ALCOHOLIC FATTY LIVER DISEASE 2009
  • INCREASED DIETARY FRUCTOSE IMPAIRS HEPATIC ATP HOMEOSTASIS IN NAFLD 2009
  • INTERACTION BETWEEN HEDGEHOG PATHWAY SIGNALING AND LEPTIN IN RAT HEPATIC STELLATE CELLS 2009
  • INTERNATIONAL COLLABORATIVE WORK: A UNIFIED LIST OF DRUGS ASSOCIATED WITH HEPATOTOXICITY AND THE REPORTING FREQUENCY OF LIVER EVENTS IN THE WHO 2009
  • NICOTINE INDUCES STEREOTYPIC FIBROGENIC CHANGES IN HUMAN PRIMARY HEPATIC STELLATE CELLS, VIA PI-3 AND P38 MAP KINASES, TRANSIDUCED THROUGH NICOTINIC ACETYLCHOLINE RECEPTORS, UPREGULATED IN HUMAN FIBROTIC NON-ALCOHOLIC STEATOHEPATITIS 2009
  • NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS WITH QUANTITATIVE ACOUSTIC RADIATION FORCE METHODS 2009
  • NOVEL ROLE FOR HEDGEHOG PATHWAY ACTIVATION IN THE PATHOGENESIS OF PRIMARY SCLEROSING CHOLANGITIS 2009
  • PHYSICAL ACTIVITY RECOMMENDATIONS, EXERCISE INTENSITY, AND HISTOLOGICAL SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE 2009
  • SERUM APOLIPOPROTEIN CIII LEVELS ARE INDEPENDENTLY ASSOCIATED WITH HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION 2009
  • STIMULATION OF LIVER-RESIDENT, BUT NOT CIRCULATING PLASMACYTOID DENDRITIC CELLS WITH TOLL-LIKE RECEPTOR AGONISTS RESULTS IN HIGH LEVELS OF INTERFERON ALPHA SECRETION DURING CHRONIC HCV INFECTION 2009
  • THE EMORY LIVER TRANSPLANT PROGRAM: EFFECTIVENESS OF A STRUCTURED COMPREHENSIVE QUALITY IMPROVEMENT INITIATIVE 2009
  • TRANSIENT HEDGEHOG PATHWAY ACTIVATION AND ACCUMULATION OF HEDGEHOG-RESPONSIVE MYOFIBROBLASTS PRECEDE EXPANSION OF LIVER EPITHELIAL PROGENITORS AFTER ACUTE CARBON TETRACHLORIDE INJURY 2009
  • PIGMENT EPITHELIUM-DERIVED FACTOR DEFICIENCY RESULTS IN INCREASED FAT MASS, HEPATIC STEATOSIS, AND INSULIN RESISTANCE 2009
  • A PHASE 2B STUDY OF TELAPREVIR WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN HEPATITIS C GENOTYPE 1 NULL AND PARTIAL RESPONDERS AND RELAPSERS FOLLOWING A PRIOR COURSE OF PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: PROVE3 INTERIM RESULTS 2008
  • A STUDY OF TELAPREVIR COMBINED WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN SUBJECTS WITH WELL-DOCUMENTED NON-RESPONSE OR RELAPSE AFTER PREVIOUS PEGINTERFERON-ALFA-2A AND RIBAVIRIN TREATMENT: INTERIM ANALYSIS 2008
  • DO GROWTH FACTORS IMPROVE SVR IN CHRONIC HCV-GENOTYPE 1 PATIENTS TREATED WITH PEG-INTERFERON AND RIBAVIRIN? 2008
  • EXOSOMES RELEASED BY HEPATIC STELLATE CELLS AND IMMATURE BILIARY EPITHELIAL CELLS CONTAIN BIOLOGICALLY-ACTIVE HEDGEHOG LIGANDS 2008
  • GENDER-SPECIFIC ASSOCIATIONS BETWEEN REGIONAL ANTHROPOMETRIC MEASURES AND HEPATIC FIBROSIS IN PATIENTS WITH NAFLD 2008
  • GENE EXPRESSION PROFILES COUPLED WITH SIGNATURES OF ONCOGENIC PATHWAY DYSREGULATION PROVIDE A RATIONAL APPROACH TO DISSECTING THE MOLECULAR HETEROGENEITY OF HEPATOCELLULAR CARCINOMA 2008
  • HEDGEHOG ACTIVATES AND MODULATES HEPATIC INVARIANT NKT (INKT) RESPONSES 2008
  • HEDGEHOG PATHWAY ACTIVATION PROMOTES HEPATIC FIBROSIS IN MICE WITH DIET-INDUCED NON-ALCOHOLIC STEATOHEPATITIS 2008
  • HEMATOLOGIC SAFETY DATA FROM THE IDEAL TRIAL: NEUTROPENIA, ANEMIA AND THROMBOCYTOPENIA PROFILES OF PEGINTERFERON ALFA/RIBAVIRIN 2008
  • HIGH PREDICTIVE ACCURACY OF AN UNBIASED PROTEOMIC PROFILE TO PREDICT SUSTAINED VIROLOGIC RESPONSE IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS 2008
  • INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN 2008
  • PARACRINE HEDGEHOG SIGNALING BETWEEN CHOLANGIOCYTES AND MYOFIBROBLASTS PROMOTES NKT CELL MIGRATION TOWARDS BILIARY EPITHELIAL CELLS: A NOVEL MECHANISM FOR NKT CELL ACCUMULATION IN PRIMARY BILIARY CIRRHOSIS 2008
  • POSSIBLE MODULATION OF ACETAMINOPHEN-ASSOCIATED LIVER INJURY BY DIVERSE CO-MEDICATIONS IN THE AERS DATABASE - A QUANTITATIVE SIGNAL DETECTION ANALYSIS 2008
  • PREDICTING THE ABILITY TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE (SVR) IN THE FIRST 12 WEEKS: RESULTS FROM THE IDEAL STUDY 2008
  • PROGRESSIVE HEDGEHOG PATHWAY ACTIVATION ACCOMPANIES THE DUCTULAR REACTION DURING NAFLD PROGRESSION IN MICE AND HUMANS 2008
  • PROPRANOLOL PROMOTES OVAL CELL ACCUMULATION BY ENHANCING HEPATOCYTE DEATH IN NON ALCOHOLIC STEATOHEPATITIS 2008
  • SUSTAINED ACTIVATION OF RAC1 ENHANCES HEDGEHOG-MEDIATED EPITHELIAL-MESENCHYMAL TRANSITION IN CULTURED RAT HEPATIC STELLATE CELLS 2008
  • SUSTAINED VIROLOGIC RESPONSE (SVR) AND PREDICTORS OF RESPONSE IN AFRICAN AMERICAN (AA) PATIENTS IN THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE 3B STUDY 2008
  • THE EFFECT OF ONE YEAR OF INTENSIVE LIFESTYLE INTERVENTION ON HEPATIC STEATOSIS 2008
  • THE PERFORMANCE OF THE AST TO PLATELET RATIO INDEX AS A NONINVASIVE MARKER OF FIBROSIS IN PEDIATRIC PATIENTS WITH CHRONIC VIRAL HEPATITIS 2008
  • TREATMENT WEEK 24 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAiVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS 2008
  • VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C 2008
  • Association of AST and ALT with liver histology in adults with NAFLD 2007
  • Fructose induced hyperuricemia as a causal mechanism for nonalcoholic fatty liver disease 2007
  • HIV entry and replication stellate cells promotes cellular activation and fibrogenesis: Implications for hepatic fibrosis in HIV/HCV co-infection 2007
  • Hedgehog signaling and epithelial mesenchymal transitions during biliary fibrosis 2007
  • Influence of impaired glucose tolerance, glucose control status, light to moderate alcohol consumption, and reduced carbohydrate diets on serum ALT change during rapid weight loss in the residential weight loss program 2007
  • Pretransplant risk factors for advanced chronic kidney disease in liver transplantation 2007
  • Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells 2007
  • Pigment epithelium-derived factor (PEDF) regulates hepatocyte lipid content through its interaction with adipose triglyceride lipase (ATGL) 2007
  • The readability of health education materials for liver transplant patients 2007
  • A novel model for harvesting adult liver progenitor cells 2006
  • Cross-talk between hepatic stellate cells and cholangiocytes regulates biliary growth through serotonin 2006
  • DGAT1 ASO treatment reduces hepatic fibrosis without improving hepatic steatosis in DB/DB mice fed methionine choline deficient diets 2006
  • DGAT2 aso treatment improves hepatic steatosis, but not fibrosis in DB/DB mice fed methionine choline deficient diets 2006
  • Influence of lifestyle factors and comorbidities on liver function in patients undergoing weight loss treatment 2006
  • Mesenchymal-epithelial signalling by the Hedgehog pathway promotes proliferation of bile ductular cells 2006
  • Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced plasminogen activator inhibitor-1 expression in human stellate cells by interfering with Smad3 phosphorylation 2006
  • Predictors of the development of de novo hepatocellular carcinoma (HCC) in patients awaiting orthotopic liver transplantation (OLT) during the meld era 2006
  • The role of hepatitis C genotype 3 core protein domain 3 in intrahepatic steatosis 2006
  • Conserved hedgehog pathway regulation of murine and human hepatic progenitors throughout life 2005
  • Elevated CD4+/CD25+ regulatory T cell number and function in acute hepatitis C genotype 1, presage chronic evolution. 2005
  • Glucose-6-phosphate dehydrogenase deficiency is associated with severe anemia during interferon and ribavirin therapy 2005
  • Hedgehog signaling in hepatic stellate cells from adult mice and rats 2005
  • Histological acute alcoholic hepatitis does not impair survival after liver transplantation 2005
  • IL-15 increases regenerative activity in the livers 2005
  • Rac over-expression in activated hepatic stellate cells increases susceptibility to liver injury 2005
  • Resolution of acute HBV infection is associated with a highest frequency and function of CD3+/CD4+/CD25+T cells. 2005
  • Activation of embryonic developmental programs in non-alcoholic fatty liver disease 2004
  • Dietary factors influence hepatic innate immune system and inflammation. 2004
  • Natural killer T cells regulate liver regeneration. 2004
  • Utility of thiopurine methyltransferase genotyping and phenotyping and measurement of 6-thioguanine metabolites in the management of autoimmune hepatitis. 2003
  • Mutivariate analysis of risk factors for chevron incisional hernia formation following liver transplantation. 2002
  • Randomized comparison of daily interferon alfa-2b and ribavirin for 24 weeks versus standard combination therapy for 48 weeks in veterans with chronic hepatitis C: Final results of a va multicenter study. 2002
  • The effect of pre-transplant MELD score on length of stay and hospital charges after orthotopic liver transplantation. 2002
  • Is nonalcoholic steatohepatitis a systemic disease? Evidence from liver transplantation. 2001
  • Is there still a role for shunt surgery in children during the era of liver transplantation? 2001
  • P-selectin mediates apoptosis of sinusoidal endothelial cells following reperfusion of the ischemic liver 1999
  • Chronic rejection after liver transplantation: Analysis of prognosis and risk factors. 1998
  • Is there a role for liver resection of non-colorectal hepatic metastases? 1998
  • Long-term effects of surgical portosystemic shunts on liver function. 1997
  • Surgical treatment of large hepatic adenomas. 1997
  • FATE OF TRANSPLANTED HEPATIC ALLOGRAFTS FROM OLDER CADAVERIC DONORS 1995
  • Combined hepatic, pancreatic, and renal retrieval from non-heart beating donors (NHBD) 1993
  • EFFECT OF CYCLOSPORINE (CSA) ON RENAL-FUNCTION IN SURVIVORS OF LIVER-TRANSPLANTATION AFTER ONE-YEAR 1993
  • ORTHOTOPIC LIVER-TRANSPLANTATION WITH REDUCED-SIZE LIVERS 1990
  • BILIRUBIN (BIL) FRACTIONS - A SIMPLE MEASURE OF LIVER GRAFT FUNCTION AND VIABILITY 1986
  • HEMODYNAMIC-CHANGES AFTER LIVER-TRANSPLANTATION 1985
  • PREDICTION OF COMPLICATIONS AND COSTS OF HEPATIC TRANSPLANTATION 1985
  • SERUM CYCLOSPORINE LEVELS FOLLOWING TRANSPLANTATION 1985